Fosun Pharma USA Inc. established in 2017, is a subsidiary of a leading global healthcare group, Fosun Pharma (SSE: 600196) (SEHK:2196) and Fosun International Limited (SEHK: 656), a leading conglomerate and investment company.
Fosun Pharma USA Inc. was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards.
Caring for others and contributing to society are other important components of our corporate responsibility. Our parent company, Fosun Pharma, partnered with Medicines for Malaria Venture (MMV) to supply 100 million doses of injectable artesunate to global markets, which have been estimated to cure more than 20 million patients with malaria.
As the U.S. market continues to be the largest pharmaceutical market in the world, these global partnerships remain vital to ensure that specialty drugs will remain accessible and affordable for several therapeutic areas.
See what specialty injectable products we offer.
Fosun Pharma USA employs a talented team with vast experience in bringing both generic and branded pharmaceuticals to market. Our U.S. team remains agile to market changes and open to opportunities in several therapeutic categories. Through it all, we remain true to our mission, vision and values.
Healthier, happier families worldwide with greater access to medicines and innovation.
To improve patient’s lives by bringing innovative and specialty drugs to the market with a commitment to excellence in quality, supply reliability and patient affordability.
Integrity: At the core of our internal operations and customer interactions we embrace high standards
Passion: We are invested and passionate about making a difference in and improving patients’ lives
Partnership: We believe stronger partnerships lead to greater success
Innovation: We recognize innovation and entrepreneurialism key to our future vision
OUR CORPORATE CULTURE
As an organization keen on learning, we provide a premier platform for employees to grow along with the company. Our cultural values focus on:
Self-improvement: The core embodiment includes the courage to introspect and correct, learning and the pursuit of lofty goals.
Teamwork: The core embodiment includes candid communication as well as coherence, integration and cooperation.
Performance: The core embodiment includes continuous innovation and result orientation.
Contribution to society: The core embodiment includes the focus on customers and achievement of win-win situations, as well as practicing what one advocates and achievement of the two ecologies.
The National Children’s Cancer Society (NCCS) secured a large quantity of Voriconazole, a drug used to treat fungal infections, for a hospital in Guatemala thanks to support from Fosun Pharma USA Inc., a new partner of the NCCS’ Michele Hertlein Global Outreach Program.
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, as well as pharmaceutical distribution and retail, with pharmaceutical manufacturing and R&D as the core, and healthcare services as the development focus.